Overview of expression of hepatitis B surface antigen in transgenic plants

Guan, Zhengjun; Guo, Bin; Huo, Yan-lin; Guan, Zheng-ping; Wei, Yahui

doi:10.1016/j.vaccine.2010.08.100

Cited by 39 publications

(21 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Again, plant-based bioreactors came into focus and first studies on expression of HBsAg in plants were performed in N. tabacum demonstrating that expression is possible in a plant system [29]. Many studies with agricultural crop like potato, banana and soybean confirmed that data and revealed the potential of oral immunization [30], [31], [49], [50]. Nevertheless, low expression levels, long growth periods and the need of agricultural areas prevented plant-based vaccination so far.…”

Section: Discussionmentioning

confidence: 99%

Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum

et al. 2011

View full text Add to dashboard Cite

Microalgae are thought to offer great potential as expression system for various industrial, therapeutic and diagnostic recombinant proteins as they combine high growth rates with all benefits of eukaryotic expression systems. Moreover, microalgae exhibit a phototrophic lifestyle like land plants, hence protein expression is fuelled by photosynthesis, which is CO2-neutral and involves only low production costs. So far, however, research on algal bioreactors for recombinant protein expression is very rare calling for further investigations in this highly promising field. In this study, we present data on the expression of a monoclonal human IgG antibody against the Hepatitis B surface protein and the respective antigen in the diatom Phaeodactylum tricornutum. Antibodies are fully-assembled and functional and accumulate to 8.7% of total soluble protein, which complies with 21 mg antibody per gram algal dry weight. The Hepatitis B surface protein is functional as well and is recognized by algae-produced and commercial antibodies.

show abstract

Section: Discussionmentioning

confidence: 99%

Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum

et al. 2011

View full text Add to dashboard Cite

show abstract

“…HBsAg has been produced in many different mammalian, microbial and plant cell systems [21][22][23]. Although large amounts of HBsAg are produced by these systems, the procedures for purifying HBsAg remain costly and time consuming.…”

Section: Discussionmentioning

confidence: 99%

Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen

Balcıoğlu¹,

Ozdemir-Bahadir²,

Hinc³

et al. 2014

ABB

View full text Add to dashboard Cite

Hepatitis B virus (HBV) is one of the major causes of chronic hepatitis, cirrhosis and liver cancer. In combating HBV infections, HBV diagnosis and vaccination are therefore critical. The hepatitis B virus surface antigen (HBsAg) is a key target molecule in developing vaccines and diagnostic systems. To date, although HBsAg has been expressed in bacteria, yeasts and mammalian cells, there are still limitations in the existing ones, which leave the necessity for searching new HBsAg production methods. In this study, a simple phage display-based method was developed to produce the purified full-length HBsAg molecules for further immunization studies. For this purpose, the HBsAg coding gene was cloned into a pCANTAB5E phagemid vector and expressed on the surface of M13 filamentous phages. The HBsAg-expressing phage nanosystem was then used as immunization agent in BALB/cJ mice. The ELISA results for sera obtained from mice immunized with HBsAg-displaying phage particles revealed an immune response against HBsAg. These results demonstrate the potential use of a full-length antigen to be displayed on phages as cost effective adjuvant-free immunization agents as an alternative to the highly purified and more expensive antigens conjugated with carrier molecules.

show abstract

“…Since the first reported plant-made HB Ag in A. tumefaciens strain LBA4404-transformated tobacco by Mason et al (1992) there has been a huge research on expressing major HBV viral proteins. Recombinant HBsAg has been expressed in lupine and lettuce (Kapusta et al, 1999), carrot suspension cells (Zhao et al, 2002), soybean (Smith et al, 2002), peanut (Chen et al, 2002), tomato (Ma et al, 2002;Carolina and Francisco, 2004;Wang and Li, 2008;Srinivas et al, 2008), cherry tomatillo (Gao et al, 2003;Guan et al, 2010), potato (Shulga et al, 2004), banana (Sunil-Kumar et al, 2005), apple core and leaves and tomato (Lou et al, 2005), NT-1 cells of tobacco (Sunil-Kumar et al, 2007) and lettuce (Kostrzak et al, 2011). Chen et al (2002) reported a high level expression of HBsAg in peanut, obtained by Agrobacterium-mediated transformation, with the yield of 2.42 µg HBsAg/g of fresh weight.…”

Section: Hepatitis Bmentioning

confidence: 99%

Production of vaccines for treatment of infectious diseases by transgenic plants

Ledl

Luthar

2016

AAS

View full text Add to dashboard Cite

Since the first pathogen antigen was expressed in transgenic plants with the aim of producing edible vaccine in early 1990s, transgenic plants have become a well-established expression system for production of alternative vaccines against various human and animal infectious diseases. The main focus of plant expression systems in the last five years has been on improving expression of well-studied antigens such as porcine reproductive and respiratory syndrome (PRRSV), bovine viral diarrhea disease virus (BVDV), footh and mouth disease virus (FMDV), hepatitis B surface antigen (HBsAg), rabies G protein, rotavirus, Newcastle disease virus (NDV), Norwalk virus capsid protein (NVCP), avian influenza virus H5N1, Escherichia coli heat-labile enterotoxin subunit B (LT-B), cholera toxin B (CT-B), human immunodeficiency virus (HIV), artherosclerosis, ebola and anthrax. Significant increases in expression have been obtained using improved expression vectors, different plant species and transformation methods.Key words: transgenic plants; vaccine production; recombinant proteins; antibodies; infectious diseases; risk assessment IZVLEČEK ZDRAVLJENJE NALEZLJIVIH BOLEZNI S CEPIVI PRIDOBLJENIMI S TRANSGENIMI RASTLINAMIPridobivanje aktivnih sestavin za cepiva s transgenimi rastlinami se je začelo v devetdesetih letih prejšnjega stoletja. Od takrat se transgene rastline uveljavljajo kot alternativni ekspresijski sistem za sintezo aktivnih komponent za cepiva proti številnim humanim in živalskim nalezljivim boleznim. V zadnjih petih letih je bil glavni poudarek razvoja namenjen optimizaciji rastlinskih ekspresijskih sistemov za dobro proučene antigene, kot so virus prašičjega respiratornega in reproduktivnega sindroma, virus goveje virusne diareje, virus parkljevke, površinski antigen hepatitisa B, G protein virusa stekline, rotavirus, virus atipične kokošje kuge, plaščni protein Norwalk virusa, sev ptičje gripe H5N1, temperaturno nestabilna B podenota enterotoksina Escherischia coli, kolera toksin B, HIV, arterioskleroza, ebola in antraks. Uporaba optimiziranih transformacijskih metod in ekspresijskih vektorjev v kombinaciji s primerno izbrano rastlinsko vrsto je v večini naštetih primerov vodila do opaznega izboljšanja sinteze posameznih učinkovin.

show abstract

Overview of expression of hepatitis B surface antigen in transgenic plants

Cited by 39 publications

References 85 publications

Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum

Algae as Protein Factories: Expression of a Human Antibody and the Respective Antigen in the Diatom Phaeodactylum tricornutum

Cost effective filamentous phage based immunization nanoparticles displaying a full-length hepatitis B virus surface antigen

Production of vaccines for treatment of infectious diseases by transgenic plants

Contact Info

Product

Resources

About